Blis Technologies [NZX: BLT] shares soared 50 percent after the biotech company said its Chinese partner planned to roll out a much wider market test of its probiotic products for mouth and throat health than it had initially indicated.
The shares jumped 1 cent to 3 cents on the NZX, the highest since November last year, valuing the company at $33 million.
The company said that following a test market trial through Sinopharm, the largest oral health and pharmaceutical company in China, its Chinese partner now planned to release Blis products in 600 pharmacies across the country, from 30 currently.
"This is still an early phase of commercialisation ," chief executive Barry Richardson told BusinessDesk. "If you think about the size of China, then it's not a large number (of pharmacies) in relation to that. Suffice to say, they are pretty positive about the development to go to the next level."
The Dunedin-based biotech company has been long in development, having first listed on the NZX in July 2001.
This article is tagged with the following keywords. Find out more about MyNBR Tags
- Big Food backs changes to s.36 of Commerce Act to curtail power of big supermarkets
- Companies Office rejects NZ First complaint over Silver Fern deal
- Light rail the winner in latest Auckland Transport turnaround
- New data series shows 5.2% of NZ households owe more than they own
- CBL attracts new business on back of the Brexit
Most listened to
- BNZ's Jason Wong says the movements in the currency market last week were some of the biggest in history
- CBL's Peter Harris on uncertain times in the UK insurance industry
- Govt performing an awkward political U-turn on foreign trusts. Rob Hosking with John Shewan and John Key
- Trade Minister Todd McClay says plans for an FTA with the EU will not be hindered by the Brexit
- Oxford University academic Malcolm McCulloch predicts the imminent death of the internal combustion engine